Arcus Biosciences
RCUS
181 hedge funds and large institutions have $1.11B invested in Arcus Biosciences in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 65 reducing their positions, and 23 closing their positions.
15% more call options, than puts
Call options by funds: $26.7M | Put options by funds: $23.2M
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
10% more capital invested
Capital invested by funds: $1.01B → $1.11B (+$98.2M)
1% more funds holding
Funds holding: 179 → 181 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 65
1.11% less ownership
Funds ownership: 75.93% → 74.82% (-1.1%)
Top Buyers
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$22M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$19.6M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$18.3M |
| 4 |
BlackRock
New York
|
-$12.7M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$12.4M |
RCUS Hedge Fund Activity: Q2 2023 in Review
181 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2023, worth a combined $1.11B — up 9.7% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RCUS positions and 23 closed out — a net gain of 3 holders — while 59 added to existing stakes and 65 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $35.5M. The largest seller was State Street, cutting an estimated $22M.
- 181 institutional investors held Arcus Biosciences (RCUS) as of Q2 2023, up from 179 in Q1 2023.
- Funds reported $1.11B of Arcus Biosciences stock for Q2 2023, up 9.7% quarter-over-quarter.
- 26 funds opened new Arcus Biosciences positions in Q2 2023 and 23 closed out, a net change of +3 holders.
- The largest Arcus Biosciences buyer in Q2 2023 was Balyasny Asset Management, an estimated $35.5M added.
- The largest Arcus Biosciences seller in Q2 2023 was State Street, an estimated $22M sold.
Based on aggregated 13F filings for Q2 2023.